blinatumomab may be seen in the settings of both MRD and also active ALL. These data support phase I/II studies with XmAb-5574 in adult ALL.
A novel view of paroxysmal nocturnal hemoglobinuria pathogenesis: more motile PNH hematopoietic stem/progenitor cells displace normal HSPCs from their niches in bone marrow due to defective adhesion, enhanced migration and mobilization in response to erythrocyte-released sphingosine-1 phosphate gradient Leukemia (2012) 26, 1722--1725; doi:10.1038/leu.2012.46
Paroxysmal nocturnal hemoglobinuria (PNH) results from the expansion of hematopoietic stem cells harboring a mutation in the PIG-A gene, which is required for the biosynthesis of glycosylphosphatidylinositol (GPI-A). 1, 2 This lipid moiety anchors dozens of different proteins to the cell surface, including some involved in resistance to complement attack, such as CD55 (Daf1 as well as proteins regulating bone marrow (BM) adhesion and retention of hematopoietic stem/progenitor cells (HSPCs). 1, 2 These associations explain why PIG-A is important for membrane lipid-raft (MLR) formation, which is believed to be involved in compartmentalizing signal transduction events within different regions of the plasma membrane and is essential for cell adhesion and migration. 3 We have already demonstrated that human PIG-Adeficient K-562 cells show profound defect in MLR formation 4 and that proper lipid-raft formation regulates chemokine receptor CXCR4---a-chemokine stromal derived factor-1 (SDF-1)-mediated adhesion of normal human HSPCs in BM, a mechanism that is crucial for BM retention of these cells. 3 MLRs are also important for proper interaction between integrin receptors expressed on HSPCs and their corresponding ligands in stem cell niches. 5 Several theories have been proposed to explain the pathogenesis of PNH and clonal expansion of PNH clones in BM. These include: (i) PNH clones escape immune attack, (ii) a second unidentified mutation gives PNH cells a growth advantage, (iii) PNH mutant cells have increased resistance to apoptosis compared with normal cells and (iv) PNH mutant cells have a deficiency in GPI-A-containing, UL16-binding proteins involved in elimination of cytomegalovirus. 1, 2 Herein, based on our already published and current data, we propose a sequence of events that over time provides an advantage to PNH HSPCs to dominate over normal HSPCs. Accordingly, based on our studies that demonstrated (i) a pivotal role for the complement cascade (CC) in mobilization of HSPCs, 6 (ii) the involvement of erythrocyte-derived bioactive lipid sphingosine-1 phosphate (S1P), which is released from erythrocytes into blood plasma during CC activation and directs egress of HSPCs from the BM into peripheral blood (PB) 7 and (iii) our studies that demonstrated that CXCR4 is a MLR receptor, 3 we hypothesize that PNH is a disorder of defective BM retention and enhanced BM migration and mobilization of HSPCs into PB.
In support of this scenario, HSPCs are retained in BM by active CXCR4 --SDF-1 and VLA-4-VCAM-1 axes 5, 6 that, as we demonstrated, counteract a steep chemottractive S1P gradient between PB plasma and BM that is present even in steady-state conditions. 7, 8 Furthermore, it has been demonstrated that the CC shows a circadian rhythm of activation, with a peak during sleep due to a drop in blood pH, 9 which explains the onset of hemolysis and hemoglobinuria at night. Moreover, because the CC is activated during infections, this additionally explains the exacerbation of PNH symptoms in patients that suffer from infection.
1,2 It has already been reported that HSPCs can be mobilized into PB during hemolytic syndromes as seen, for example, during acute crisis in sickle-cell anemia patients, however, the factors involved in this phenomenon were not clearly identified. þ FLAER þ (normal) and CD34 þ FLAER À (PNH) cells sorted from PB, stimulated by SDF-1 (50 ng/ml) þ LL-37 (2.5 mg/ml), stained with cholera toxin-B subunit conjugated with FITC (lipid-raft marker), rabbit anti-hCXCR4 antibody and anti-rabbit Alexa Fluor594 and evaluated by employing confocal microscopy for formation of MLRs. White areas indicate colocalization of CXCR4 in MRL. It can be seen that MLRs were formed in CD34 
(d) FLAER
À HSPCs from PB show enhanced chemotaxis in response to an SDF-1 gradient. FLAER þ (normal) and FLAER À (PNH) cells were sorted from PB-lymphocyte gate and tested in a chemotaxis assay for their responsiveness to an SDF-1 gradient. Cells (10 5 ) were plated in upper chambers of TransWell systems and were collected from the lower chambers after chemotaxis and evaluated for the number of clonogenic CFU-Mix. Data from 10 separate experiments are pooled together. *Po0.0001 compared with untreated controls.
Letters to the Editor Therefore, to explain mobilization in hemolytic syndromes, we propose based on our previous work on a role of CC and bioactive lipids in mobilization 7, 8 that the major factor that directs egress of HSPCs into PB is S1P released from erythrocytes exposed to C5b-C9 (membrane-attack complex (MAC)), the final product of CC activation. It is well known that erythrocytes are highly enriched for this bioactive lipid 8 and erythrocyte lysates chemoattract HSPCs in S1P-dependent manner (Supplementary Figure 1) . Thus, activation of CC in PB due to circadian rhythms 9 and, most importantly, due to infections may trigger release of S1P from erythrocytes in a MAC-dependent manner. S1P in turn provides a chemotactic gradient and preferentially mobilizes less adherent PNH HSPCs into PB.
To Supplementary Figure 2 .
Mobilization of normal and PNH-affected HSPCs was evaluated in the past by another group 12 and in contrast to our observations as reported, normal HSPCs was the predominant population of HSPCs circulating in PB in steady-state conditions. This discrepancy could be explained by the fact that while we were using more sensitive FLAER-based analysis, the other group employed lack of CD59 expression on cell surface as a marker of PNH cells. 13 The same authors, however, reported in agreement with our hypothesis that G-CSF administration preferentially mobilized PNH-affected cells. 12 To explain this at mechanistic level, we already reported that G-CSF activates CC in BM and thus increases MAC-mediated release of S1P from erythrocytes, 7 which provides a strong chemotactic gradient for HSPCs in PB.
To further support our hypothesis and to explain the enhanced mobilization of PNH CD34
þ cells into PB, we focused on adhesion to fibronectin and SDF-1 of FLAER þ and FLAER À cells sorted from the lymphocyte gate. Figure 1a shows defective adhesion of PNH cells, which may explain impaired retention of PNH HSPCs in BM. Next, because adhesion to fibronectin and SDF-1 is mediated by integrin and CXCR4 receptors, respectively, which are known as MLR-associated receptors, 3 we evaluated MLR formation on FLAER þ CD34 þ and FLAER À CD34 þ cells sorted from the PB of a PNH patient. In this assay, based on the fact that the antimicrobial cationic peptide cathelicidin (LL-37), which is secreted by BM stromal cells and granulocytes, enhances incorporation of CXCR4 into MLRs, 14 we exposed these cells to a low dose of SDF-1 þ LL-37 and performed confocal analysis of MLR formation. As demonstrated in Figure 1b , PNH-affected FLAER
þ cells, when plated in the polylysine-covered glass dishes, display a defect in actin polymerization (Figure 1c) . Thus, a defect in MLR formation that affects the pro-adhesive properties of FLAER À Figure 2 . PNH as a disease of increased mobility of PNH clones that may give them a growth advantage over normal HSPCs. PNH HSPCs, due to a GPI-A-mediated defect in lipid-raft formation, have impaired adhesion in BM niches (1), resulting in their enhanced egress (mobilization) from the BM into PB in response to an S1P gradient (2) and enhanced mobility in the BM microenvironment (3). Based on this finding, PNH HSPCs, which show higher motility than their normal healthy counterparts, outcompete and outgrow normal HSPCs in the BM microenvironment over time (4) . Over time, this defect in adhesion of PNH HSPCs in BM microenvironment and their defective interaction with cellular and extracellular elements in hematopoietic niche may trigger malignant transformation of HSPCs that leads to development of leukemia. We also propose that S1P released from erythrocytes together with activation of CC may have a crucial role in mobilization of HSPCs in other hemolytic syndromes such as, for example, during hemolytic crisis in sickle-cell anemia patients.
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CD34 À cells is probably the main reason for their increased mobility within BM and preferential egress in response to an S1P gradient from BM into PB. S1P binds to five G ai -protein-coupled receptors from which S1P1 and S1P3 enhance chemotaxis and adhesion. 8, 13 However, our data on the migration of HSPCs in response to an S1P gradient indicate that S1P receptors (S1P1 and S1P3) are not MLRassociated. 13 The fact that S1P1 and S1P3 signaling do not depend on MLR formation explains the robust mobilization of HSPCs by an S1P plasma gradient.
Next, because PNH HSPCs show defective adhesion to dishes covered with immobilized SDF-1 and fibronectin (a situation that mimics their adhesion in BM niches), we became interested in their migratory responsiveness to an SDF-1 gradient. This interest was justified by the fact that for maximal signaling, CXCR4 in contrast to S1P1 and S1P3 must be incorporated into MLR. 3 Thus to address the role of SDF-1, we employed TransWell chemotaxis assays in response to an SDF-1 gradient and observed, to our surprise, that this responsiveness was enhanced for PNH FLAER À HSPCs compared with their normal FLAER þ counterparts (Figure 1d ). Based on this, our chemotaxis experiments with SDF-1 suggest that MLR are more important in adhesion than in migration of HSPCs. This seems to be a reasonable explanation, because these are opposing effects.
Therefore, our data may explain, on the one hand, why HSPCs are highly mobile in the BM microenvironment and are more sensitive to S1P-directed mobilization into PB. On the other hand, this also explains why they home back into BM in response to a BM SDF-1 gradient, as well as to other homing-factor gradients (for example, ceramide-1 phosphate and ATP). 13, 15 Thus in this sequence of events triggered by enhanced motility, PNH HSPCs over time outcompete normal HSPCs from their hematopoietic niches. Thus, the mutation of PIG-A, a gene involved in MLR formation that does not possesses any oncogenic or antioncogenic properties, may lead over time to expansion of PNH clones in BM.
In conclusion, our data on the analysis of FLAER À CD34 þ and FLAER þ CD34 þ cells in a PB-lymphocyte gate indicates preferential release of PNH-affected HSPCs. Furthermore, studies are in progress to evaluate adhesive and migratory properties of HSPCs isolated directly from the BM of PNH patients. It is also important to evaluate whether eculizumab, a humanized monoclonal antibody directed against C5 that is employed in treatment of PNH, inhibits by decreasing C5b-C9 (MAC) plasma level, MACinduced release of S1P from erythrocytes, and thus prevents mobilization of PNH-affected HSPCs. Our data in C5-deficient mice, which do not generate MAC and are poor mobilizers, predict that this would be the case. 16 Based on the foregoing, Figure 2 illustrates our novel hypothesis about the pathogenesis of PNH. Based on this, we also propose that S1P released from erythrocytes together with activation of CC may have a similar role in mobilization of HSPCs in other hemolytic syndromes such as, for example, during hemolytic crisis in sickle-cell anemia patients. 10 
